ArticleHaematologica2020
Immunologic characterization of COVID-19 patients with hematological cancer.
Abstract readLetter
In one paragraph
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Immune response dynamics of SARS-CoV-2 vaccination in chronic lymphocytic leukemia individuals: a descriptive analysis.Frontiers in immunology · 2025Article
- Effectiveness of early intervention and combination treatment with monoclonal antibodies and antivirals in oncohematological patients with SARS-CoV-2: a retrospective experience.Frontiers in immunology · 2025Article
- Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.Frontiers in oncology · 2023Article
- Cancer, more than a "COVID-19 co-morbidity".Frontiers in oncology · 2023Review
- Article
- In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection.Scientific reports · 2022Article
- COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP.Blood advances · 2022Article
- Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection.Cancers · 2022Article
- COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response.Acta haematologica · 2022Review
- Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies.Blood cancer journal · 2021Article
- Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.Blood cancer journal · 2021Observational
- Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing.Cell death & disease · 2021Article
- Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility.Journal of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Catarina MaiaClinica Universidad de Navarra, Pamplona, Spain; Centro de Investigacion Medica Aplicada (CIMA), Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00369, Pamplona.
Esperanza Martín-SánchezClinica Universidad de Navarra, Pamplona, Spain; Centro de Investigacion Medica Aplicada (CIMA), Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00369, Pamplona.
Juan José GarcésClinica Universidad de Navarra, Pamplona, Spain; Centro de Investigacion Medica Aplicada (CIMA), Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00369, Pamplona.
Ascensión López-Díaz De CerioClinica Universidad de Navarra, Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00489, Pamplona.
Susana InogésClinica Universidad de Navarra, Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00489, Pamplona.
Manuel F LandechoClinica Universidad de Navarra, Pamplona.
Belén Gil-AlzugarayClinica Universidad de Navarra, Madrid.
Cristina PerezCentro de Investigacion Medica Aplicada (CIMA), Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00369, Pamplona.
Cirino BottaHospital "Annunziata", Cosenza.
Aintzane ZabaletaClinica Universidad de Navarra, Pamplona, Spain; Centro de Investigacion Medica Aplicada (CIMA), Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00369, Pamplona.
Félix AlegreClinica Universidad de Navarra, Pamplona.
César RincónClinica Universidad de Navarra, Madrid.
Laura BlancoInstituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00369, Pamplona.
Sarai SarvideCentro de Investigacion Medica Aplicada (CIMA), Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00369, Pamplona.
Amaia Vilas-ZornozaCentro de Investigacion Medica Aplicada (CIMA), Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00489, Pamplona.
Diego AlignaniClinica Universidad de Navarra, Pamplona, Spain; Centro de Investigacion Medica Aplicada (CIMA), Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00369, Pamplona.
Cristina MorenoClinica Universidad de Navarra, Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00369, Pamplona.
Artur PaivaCentro Hospitalar e Universitário de Coimbra, Coimbra.
António MartinhoCentro de Sangue e Transplantação de Coimbra, Instituto Português do Sangue e da Transplantação, Coimbra.
Rui AlvesCentro Hospitalar e Universitário de Coimbra, Coimbra.
Enrique ColadoHospital Universitario Central de Asturias, Oviedo.
Covadonga QuirósHospital Universitario Central de Asturias, Oviedo.
Mónica OlidClinica Universidad de Navarra, Madrid.
Andrés BlancoClinica Universidad de Navarra, Pamplona.
Josepmaria ArgemiClinica Universidad de Navarra, Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona.
Bruno PaivaClinica Universidad de Navarra, Pamplona, Spain; Centro de Investigacion Medica Aplicada (CIMA), Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona, Spain; CIBER-ONC number CB16/12/00369, Pamplona.
José Ramón YusteClinica Universidad de Navarra, Pamplona, Spain; Instituto de Investigacion Sanitaria de Navarra (IdiSNA), Pamplona. jryuste@unav.es.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Not available.
Indexed as
COVID-19Hematologic NeoplasmsHumansSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.